Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML
NCT04493099 · M.D. Anderson Cancer Center · PHASE1/PHASE2 · withdrawn · last registry update 2020-11-12 · Acute myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The original sponsor was acquired by a new company and has elected to end funding for all Investigator Sponsored Trials (ISTs)” | Open Targets' class: business administrative | Registry record, M.D. Anderson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against BCL2 in acute myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-01-13Phase 3 first posted: M.D. Anderson Cancer Center, Busulfan + Cladribine (NCT04708054)
- 2020-11-13Phase 3 first posted: University of Ulm, Venetoclax + Placebo (NCT04628026)
- 2020-02-28Results posted on the registry: AbbVie, Placebo + Venetoclax (NCT03069352)
- 2020-02-05Phase 3 first posted: Taiho Oncology, Inc., Azacitidine + ASTX030 (cedazuridine + azacitidine) (NCT04256317)
- 2019-11-13Phase 3 first posted: AbbVie, Venetoclax + Azacitidine (NCT04161885)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision